Stellus Rx Acquires Tria Health to Expand Pharmacist-Led Care

Stellus Rx, a technology-enabled pharmacy care management company based in Plano, Texas and backed by WindRose Health Investors, announced on April 16, 2026, that it has acquired Tria Health, a Kansas City, Missouri-based provider specializing in pharmacist-led support for chronic conditions. The acquisition aims to build a unified platform that enhances clinical outcomes and reduces healthcare costs for self-insured employers, value-based care organizations, and other risk-bearing stakeholders.

Financial terms of the transaction were not disclosed. Both companies will continue to operate under their existing brands in the near term while working to integrate their capabilities and expand their reach.

Stellus Rx delivers pharmacist-led patient support and dispensing solutions designed to optimize medication use and promote healthier behaviors, particularly for patients with chronic and complex conditions. The company partners with healthcare providers, payors, employers, and risk-bearing entities to improve health outcomes and reduce total cost of care nationwide.

Tria Health offers personalized pharmacy expertise through comprehensive medication and lifestyle reviews for individuals with chronic conditions. Its services are primarily delivered to members of self-insured employers, focusing on improving health literacy, closing care gaps, and simplifying benefits to enhance outcomes and reduce costs.

According to Tony Willoughby, CEO of Stellus Rx, “Too many organizations are leaving value on the table–and, more importantly, patient outcomes suffer–because people don’t have the support they need to take the right medications as prescribed. By bringing Stellus Rx and Tria Health together, we’re creating a pharmacist-led platform that helps organizations realize the full clinical and financial impact of effective medication use.” Jessica Lea, CEO of Tria Health, added, “This marks an exciting next chapter for our team and our clients, allowing us to expand our impact while advancing the care model that has made Tria Health successful.”

The acquisition is backed by WindRose Health Investors, a New York City-based private equity firm with approximately $7 billion under management, focused on healthcare services companies with profitable and cost-effective business models. David Masterman, Principal at WindRose, stated, “We believe this combination creates a differentiated platform with the ability to deliver meaningful clinical impact while reducing total cost of care for a broad set of stakeholders.”

Strategically, the deal strengthens Stellus Rx’s position as a leading pharmacist-led healthcare platform by broadening clinical capabilities and client reach. The combined entity plans to leverage cross-selling opportunities, expand service offerings to risk-bearing entities and employer groups, and utilize integrated data analytics to optimize medication adherence and cost management.

Industry trends show increasing demand for pharmacist-led interventions and value-based care models that improve patient outcomes while controlling costs. This acquisition accelerates consolidation in the pharmacy services sector and intensifies competitive pressure on traditional pharmacy benefit managers and healthcare providers.

Financial advisors on the deal included Piper Sandler & Co. for Tria Health, with legal counsel provided by McDermott Will & Schulte LLP for Stellus Rx and Stinson LLP for Tria Health.

Looking ahead, the companies will focus on integrating technology platforms, aligning operational processes, and maintaining patient experience continuity. The combined platform aims to unlock greater clinical and economic value by applying shared learnings across adjacent markets with similar needs.

As the healthcare industry continues to emphasize personalized, pharmacist-led care, this acquisition positions Stellus Rx and Tria Health to deliver enhanced support for patients managing chronic conditions, ultimately driving improved health outcomes and reduced total cost of care.